Christopher Wilson, PhD

Dr. Wilson  is developing molecular tools to specifically modify RNA as a potential pathway to novel cancer therapeutics. RNA modification affects RNA fate and influences the way genes are expressed, including cell cycle control, cell differentiation, and transcript stability, which have been linked to a variety of diseases, including cancer. Dr.

Monica E. McCallum, PhD

Dr. McCallum studies a compound, called alanosine, which exhibits anti-cancer activity against cells from sarcomas, mesothelioma, and pancreatic cancer. This compound is produced by a soil-dwelling bacterium. She seeks to elucidate how bacteria produce alanosine. Understanding the genes and enzymes that assemble this molecule will guide the discovery of additional novel chemotherapeutic agents that may be produced by bacteria.

Philip B. Abitua, PhD

Dr. Abitua studies the development of the African turquoise killifish, Nothobranchius furzeri, a promising model organism to investigate cell migration in vivo. He seeks to understand how cells aggregate through a mesenchymal to epithelial transition (MET) during embryogenesis. Using light sheet microscopy, he plans to image and analyze this highly dynamic phenomenon in order to make predictions about how cells decide to change their behavior during MET, an understudied process that is casual for malignancy. 

Sungwook Woo, PhD

Dr. Woo [HHMI Fellow] is using protein structures to illustrate the mechanisms of cancer-related processes. His research aims to overcome limitations of current techniques by using recent breakthroughs in “programmable DNA self-assembly” to develop protein framework structures that contain “pockets” with tunable size and shape for structural studies. If successful, his efforts will provide a general tool for structural biology and in turn benefit the mechanistic studies and therapeutic development for cancer.